Economic challenges and possible policy actions to advance stratified medicine

Personalized Medicine

Volumn 9, Issue 4, 2012, Pages 413-427

  Trusheim, Mark R ^a   Berndt, Ernst R ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

economics of personalized medicine; health economics; personalized medicine incentives; stratified medicine

Indexed keywords

CETUXIMAB; CRIZOTINIB; GEFITINIB; IMATINIB; IPILIMUMAB; PANITUMUMAB; PNEUMOCOCCUS VACCINE; SIPULEUCEL T; TRASTUZUMAB; VEMURAFENIB;

BREAST CANCER; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; PATENT; PERSONALIZED MEDICINE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW;

EID: 84862726370     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.12.35     Document Type: Review

References (63)

1. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Disc. 6, 287-293 (2007).
2. Frueh FW, Amur S, Mummaneni P et al. Pharmacogenic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy 28(8), 992-998 (2008).
3. Woodcock J. The prospects for 'personalized medicine' in drug development and drug therapy. Clin. Pharmacol. Ther. 81, 164-169 (2007).
4. Trusheim MR, Burgess B, Xinghua Hu S et al. Quantifying stratified medicine success factors: a multi-stakeholder perspective. Nat. Rev. Drug Disc. 10(11), 817-833 (2011). US FDA, academic and industry consortium modeling analysis of the critical drivers affecting the economics of developing stratified medicines. It includes one CNS and two oncology case studies.
5. Institute of Medicine. Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary. The National Academies Press Washington, DC, USA (2010). Multistakeholder, independent review of the challenges and costs of developing stratified medicines in oncology with potential policy implications.
6. Pegram MD, Pauletti G, Slamon DJ. HER-2/ neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. 52(1-3), 65-77 (1998).
7. Amodol RG, Wolf M, Freeman D et al. Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy. Eur. J. Cancer Suppl. 5, 8 (2007).
8. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J. Clin. Oncol. 25(2), 209-216 (2007). An analysis of the reduction in oncology patient populations for any individual medicine due to the scientific molecular segmentation of the disease and the number of targeted therapies.
9. US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2004 Incidence and Mortality Web-Based Report. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, GA, USA (2007).
10. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst. 101, 1044-1048 (2009). An analysis of the combined cost to payers if all oncology personalized medicines command increasingly high prices and obtain widespread usage.
11. Chiang A, Million RP. Personalized medicine in oncology: next generation. Nat. Rev. Drug Disc. 10(12), 895-896 (2011).
12. Pollack A. Approval for drug that treats melanoma. New York Times, 25 March (2011). n A description of the recent oncology product launches, including their pricing.
13. Woelderink A, Ibarreta D, Hopkins MM and Rodriguez-Cerezo E. The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J. 6, 3-7 (2006).
14. Loupakis F, Vasile E, Santini D, Masi G, Falcone A, Graziano F. EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. Pharmacogenomics 9(1), 55-69 (2008).
15. Radack DV. GATT brings major changes in U.S. patent law. JOM 47(5), 79 (1995).
16. Gottlieb S. The FDA is evading the law. Wall Street Journal, 23 December (2010).
17. Ridley DA, Grabowski HG, Moe J. Developing drugs for developing countries. Health Affairs 25(2), 313-324 (2006).
18. Berndt ER, Gottschalk AHB, Strobeck MW. Opportunities for improving the drug development process: results from a survey of industry and the FDA. In: Innovation Policy and the Economy. Jaffe AB, Lerner J, Stern SM (Eds). MIT Press for the National Bureau of Economic Research, MA, USA, 91-121 (2006).
19. Woosley RL, Rice G. A new system for moving drugs to market. Issues Sci. Technol. 21(2), 63-68 (2005). A compelling case for revising the regulatory approval process to provide faster, appropriate access to emerging therapies and to continue learning about those therapies postapproval.
20. Eichler HG, Oye K, Baird LG et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91(3), 426-437 (2012).
21. Chabner BA. Early accelerated approval for highly targeted cancer drugs. N. Engl. J. Med. 364(12), 1087-1089 (2011).
22. McClellan M, Benner J, Schlisky R et al. An accelerated pathway for targeted cancer therapies. Nature Rev. Drug Disc. 10(2), 79-80 (2011).
23. Fox FL. NCATS launches. Nat. Biotechnol. 30, 204 (2012).
24. Berndt ER, Hurvitz JA. Vaccine advance - purchase agreements for low-income countries: practical issues. Health Affairs 24(3), 653-665 (2005).
25. Kremer M and Williams H. Incentivizing innovation: adding to the tool kit. In: Innovation Policy and the Economy. Lerner J, Stern SM (Eds). MIT Press for the National Bureau of Economic Research, MA, USA, 1-17 (2010).
26. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J. Health Econ. 22(2), 141-185 (2003).
27. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Research and development costs for new drugs by therapeutic category: a study of the US pharmaceutical industry. Pharmacoeconomics 7, 152-160 (1995).
28. DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: is biotech different? Manage. Decis. Econ. 28, 469-479 (2007).
29. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Affairs 25(2), 420-428 (2006).
30. Walker I, Newell H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat. Rev. Drug Disc. 8(1), 15-16 (2009).
31. Abrantes-Metz RM, Adams CP, Metz AD. Pharmaceutical development phases: a duration analysis. J. Pharmaceutical Finance Econ. Policy 14(4), 19-42 (2005).
32. Stern D, Reissman D. Specialty pharmacy cost management strategies of private health care payers. J. Manag. Care Pharm. 12(9), 736-744 (2006).
33. US FDA clears Abbott's companion Dx for Pfizer's NSCLC Drug. GenomeWeb Daily News. 29 August 2011. www.genomeweb.com/mdx/fda-clearsabbotts-companion- dx-pfizers-nsclc-drug (Accessed 6 January 2012)
34. Jefferson E. US FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer. FDA News Release. 26 August 2011. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm (Accessed 6 January 2012)
35. McHale D. Current experience with stratified medicines & current drugs in development. Presented at: Fifth Forum of the Ministerial Industry Strategy Group (MISG) UK MHRA. 9 October 2009. www.mhra.gov.uk/home/groups/es- policy/documents/websiteresources/con065595.pdf (Accessed 17 June 2011)
36. US Department of Health and Human Services, US FDA. FY 2011 innovative drug approvals. www.fda.gov/downloads/aboutfda/reportsmanualsforms/reports/ ucm278358.pdf (Accessed 1 February 2012)
37. American Cancer Society. Cancer Facts and Figures 2010. American Cancer Society No. 500810. 2. (2010). www.cancer.org/Research/CancerFactsFigures/ CancerFactsFigures/cancer-facts-and-figures-2010 (Accessed 17 June 2011)
38. Associated Press. $93,000 cancer drug: how much is a life worth? Boston Herald 27 September 2010. http://news.bostonherald.com/business/ healthcare/view/2010092793000-cancer-drug-how-much-is-a-life-worth/srvc= home&position=recent (Accessed 17 June 2011)
39. Mucahy N. Time to consider cost in evaluating cancer drugs in United States? Medscape News Today. www.medscape.com/viewarticle/705689 (Accessed 14 June 2011)
40. Melanoma (stage III or IV) - ipilimumab: appraisal consultation document. NHS NICE 14 October 2011. http://guidance.nice.org.uk/TA/WaveCRS2/48/ Consultation/DraftGuidance (Accessed 6 January 2012)
41. Kobelt G et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the USA. SSE/EFI Working Paper Series in Economics and Finance 594 (Dec 2004). http://swopec.hhs.se/hastef/papers/hastef0594.pdf (Accessed 17 June 2011)
42. Recap by Deloitte. www.recap.com (Accessed 11 February 2011)
43. Albainy-Jenei S. Three-year market exclusivity extension for a new indication of a drug. Patent Baristas 7 March 2006. www.patentbaristas.com/ archives/2006/03/07/three-year-marketexclusivity-extension-for-a-new-indication- ofa-drug/ (Accessed 17 June 2011).
44. US FDA. Frequently asked questions on pediatric exclusivity (505a), the pediatric 'rule', and their interaction. www.fda.gov/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/ucm077915.htm (Accessed 17 June 2011)
45. US Patent Office. Manual of patent examining procedures (MPEP) 2755.02 Interim Extension of Patent Term Before Product Approval - 2700 Patent Terms and Extensions. USPTO Edition 8(E8) August 2001, last revision July 2010. www.uspto.gov/web/offices/pac/mpep/documents/2700-2755-02.htm (Accessed 17 June 2011)
46. Copyright Term Extension Act of 1998, S.505, 27 January 1998. www.copyright.gov/legislation/s505.pdf (Accessed 18 December 2010)
47. US FDA. CFR-Code of Federal Regulations Title 21. www.accessdata.fda.gov/ scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=314&showFR= 1&subpartNode=21:5.0.1.1.4.8 (Accessed 17 June 2011).
48. US FDA. US FDA approves coartem tablets to treat malaria. News release, 8 April 2009. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149559.htm (Accessed 17 June 2011)
49. Advance Market Commitments for Vaccines. The pneumococcal AMC: ready to save lives. www.vaccineamc.org (Accessed 17 June 2011)
50. Advance Market Commitments for Vaccines. Update: GAVI Partners Fulfill Promise To Fight Pneumococcal Disease. News release 12 June 2009. www.vaccineamc.org/updatejun-09.html (Accessed 17 June 2011)
51. Advance Market Commitments for Vaccines. Update: GSK vaccine receives AMC approval by Independent Assessment Committee. News release 7 May 2010. www.vaccineamc.org/updatemay7-10.html (Accessed 17 June 2011)
52. Advance Market Commitments for Vaccines. Pfizer vaccine receives AMC approval by Independent Assessment Committee. Press release, 10 September 2010. www.vaccineamc.org/updatesept10-10.html (Accessed 17 June 2011)
53. Glassman A. Break out the champagne! The AMC delivers vaccine. Center for Global Development, 13 December 2010. http://blogs.cgdev.org/globalhealth/2010/ 12/break-out-the-champagne-the-amc-deliversvaccines.phpl (Accessed 17 June 2011)
54. Nord J, Lynn K. Pawlenty approves 'angel' tax credit bill. Mndaily.com 4 April 2010. www.mndaily.com/2010/04/04/pawlentyapproves-%E2%80%98angel%E2%80%99- tax-credit-bill (Accessed 17 June 2011)
55. Lee J. President Obama signs small business jobs act-learn what's in it. 2010 September 27 In: The White House blog. www.whitehouse.gov/blog/2010/09/27/ president-obama-signs-small-business-jobsact-learn-whats-it (Accessed 17 June 2011)
56. Sterk J. Assessing the impact of tumor evolution on oncology drug development and commercialization. Unpublished SM thesis, Harvard-MIT Division of Health Sciences and Technology, MA, USA (June 2011). http://dspace.mit.edu/ handle/1721.1/65523 (Accessed 9 January 2012) A Masters thesis demonstrating that despite strong scientific hypotheses, developing a chronic myeloid leukemia medicine for the small drug-resistant population is not economically viable under nearly any current scenario.
57. Lucarelli C, Nicholson S. A quality-adjusted price index for colorectal cancer drugs. NBER Working Paper No. 15174 (July 2009). www.nber.org/papers/ w15174 (Accessed 6 May 2012)
58. Yee CM. New model aims to put brakes on rising cost of cancer care. Minneapolis Star Tribune October 19, 2010. www.startribune.com/business/ 105312318.html?elr=KArksUUUoDEy3LGDiO7ai (Accessed 17 June 2011)
59. Petttypiece S. Bristol-Myers Sprycel Drug Beats Gleevec in Leukemia Patients, Study Says. Bloomberg News (5 June 2010). www.bloomberg.com/news/2010- 2006-05/bristol-myers-sprycel-drug-beats-gleevec-inleukemia-patients-study-says. html (Accessed 17 June 2011)
60. Sabir SA. The economic and ethical considerations and implications of the stratification of future oncology therapeutics. Unpublished SM thesis, Harvard-MIT Division of Health Sciences and Technology, MA, USA (June 2009). http://hdl.handle.net/1721.1/54674 (Accessed 17 June 2011)
61. Austin DH, Kyle J, Moore D. Research and development in the pharmaceutical industry. Congressional Budget Office Pub No. 2589 (October 2006). www.cbo.gov/sites/default/files/cbofiles/ftpdocs/76xx/doc7615/10-02- drugr-d.pdf (Accessed 6 May 2012)
62. Office of Technology Assessment. Pharmaceutical R&D: costs, risks and rewards, OTA-H-522 (February 1993). www.fas.org/ota/reports/9336.pdf (Accessed 6 May 2012)
63. PriceWaterhouseCoopers MoneyTree™report. www.pwcmoneytree.com (Accessed 11 February 2011)